Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

Investors may be wary of PPLPHARMA as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 60.032215
debtToEquity 60.533000
earningsGrowth -0.625000
revenueGrowth 0.125000
grossMargins 0.597880
operatingMargins 0.063940
trailingEps 0.340000
forwardEps 0.000000

Piramal Pharma Limited's forward PE is too high, signaling potential overvaluation. This could cap future price increases and trigger a correction. Investors should carefully analyze this metric along with other fundamental indicators before making investment decisions.
Piramal Pharma Limited's low earnings and revenue growth highlight a potential decline in profitability. This suggests that the company's financial health may be weakening, and profits could shrink as a result.
With negative gross and operating margins, PPLPHARMA is facing losses at both the production and operational levels. This signals significant financial strain and may indicate that the company is struggling to manage costs effectively.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA



Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


The recent buy bias from analysts suggests Piramal Pharma Limited is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, Piramal Pharma Limited appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.